Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,361 across all filing types
Latest filing 2024-05-16 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
北京市中勤律师事务所关于亚宝药业集团股份有限公司2023年年度股东大会律师见证法律意见书
Regulatory Filings
2024-05-16 Chinese
亚宝药业集团股份有限公司2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a "2023 Annual General Meeting Resolution Announcement" for 亚宝药业集团股份有限公司. It details the date and location of the AGM, attendance, voting results on various proposals including the 2023 annual report, board reports, financial statements, profit distribution plan, and other corporate governance matters. The document includes voting percentages and confirms the legality and validity of the meeting and resolutions. It does not contain the full annual report or financial statements themselves but rather the official announcement of the resolutions passed at the AGM. The document length is 4512 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-05-16 Chinese
亚宝药业集团股份有限公司关于参加山西辖区上市公司2024年投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an online investor interaction event organized by regulatory and industry bodies. It mentions the company will discuss its 2023 annual performance, governance, strategy, financing plans, and other topics during the event. The document is short (565 characters) and serves as a notice of the event rather than containing any financial data or detailed report. It does not contain actual financial statements or detailed analysis, nor is it a transcript or presentation. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2024-05-14 Chinese
亚宝药业集团股份有限公司2023年年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as "2023 年年度股东大会会议资料" which translates to "2023 Annual General Meeting (AGM) materials". It contains detailed agenda items for the AGM, including the presentation and review of the 2023 Annual Report, Board of Directors' work report, Supervisory Board report, financial statements, profit distribution plan, and other governance matters. The document includes meeting procedures, voting instructions, and detailed reports that are typically presented and discussed during an AGM. The presence of voting procedures and agenda items confirms this is material prepared for the Annual General Meeting rather than the report itself or an announcement of the report. The document length (15,000 characters) and content depth support it being the AGM materials rather than a brief announcement or a standalone report. Therefore, the document fits the category of AGM Information (AGM-R).
2024-05-09 Chinese
亚宝药业集团股份有限公司关于获得药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a pharmaceutical company about receiving an official approval notice from the National Medical Products Administration regarding a drug supplement application. It details the drug's specifications, approval, production plans, and sales figures. The document is short (1438 characters) and serves as a formal announcement of regulatory approval rather than a detailed financial report or management discussion. It does not contain financial statements or comprehensive financial analysis. It is not a report publication announcement since it does not mention the release or availability of a report. It is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about drug approval and related information that does not fit other specific categories.
2024-04-28 Chinese
亚宝药业集团股份有限公司关于控股股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by the controlling shareholder of the company. It details the number of shares pledged, the proportion of total shares, and related information about the pledge. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledge (a form of capital/financing update). It is not a full financial report or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short and focused on a specific financing-related event (share pledge).
2024-04-26 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.